Affitech in brief
Affitech A/S discovers and develops drugs based on fully human antibodies for cancer and other diseases with high unmet medical needs utilizing its fully integrated antibody library and proprietary screening platforms.
Affitech A/S has built a substantial pipeline of early stage fully human antibody drug candidates using the MBASTM and CBASTM methods and targeting VEGF (Vascular Endothelial Growth Factor) and GPCR (G-protein coupled receptors). The Company is developing a novel anti-VEGF antibody AT001/r84 with a unique specificity that may offer improved anti-angiogenesis therapy.
Formed in 2009
- Business combination of Affitech AS (Norway) and Pharmexa A/S (Denmark)
- Located in Copenhagen Bio Science Park (COBIS) and the Research Park in Oslo
- Experienced Management and Board of Directors
- Skilled international organization: 30+ people (27 scientists, 10 PhDs)
Listing details:
- Listed on Nasdaq OMX Copenhagen
- Market Cap of DKK 220m
- Ownership: TransNova Inv. Ltd.: 40%, Krosalter Enterprises Ltd. 13,3%, Norwegian PE and institutions: ~30%, Danish private investors: ~17%
Partners
- IBC Generium: Exclusive rights in Russia and CIS for VEGF antibody AT001/r84 and GPCR antibody programme AT008
- Roche:AT004
- Peregrine Pharmaceuticals: AT005
